Tags: Drug.
Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity schizophrenia Alzheimer’s disease Parkinson’s disease and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression.
